Hospira recalls another product made at Australian plant cited by FDA

Hospira ($HSP) is recalling another product manufactured at a plant in Australia, which last year received an FDA warning letter. The Lake Forest, IL-based company is voluntarily recalling 3,306 vials of the cancer drug dacarbazine because of discoloration, according to the most recent FDA Enforcement Report. It said the reconstituted solution may appear pink instead of colorless to pale yellow when stored according to labeled conditions. The drug came from its plant in Mulgrave, Victoria, which was issued a warning letter by the FDA in September for its tardiness in investigating out-of-specification test results in some products. One of those products was the cancer med mitoxantrone. Last month, the company began recalling 10 lots of that drug. Report | More

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

CureVac has tapped Wacker to help produce 100 million doses of its mRNA-based COVID-19 vaccine at its Amsterdam facility.